Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
120 participants
INTERVENTIONAL
2022-12-31
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study is based on the following hypotheses:
* Infection and the interferon response to infection may induce hyperactive or immunosuppressive differentiation of myeloid cells, that may be treated by specific inhibitors.
* Some myeloid cell subpopulations currently identified in our laboratories might be markers for Covid-19 prognosis.
* Alternative receptors may be present on myeloid cells, inducing the cytokine storm, a target for therapy.
* The expression of Interferon (IFN) receptor and IFN responding genes on myeloid cells and on respiratory epithelial cells may correlate with prognosis and indicate potential treatment targets.
* Interferon responses are known to be skewed during Covid-19, but some IFN subtype polymorphisms may correlate with prognosis and these subtypes migt be supplemented or inhibited for therapy.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multiparametric Assessment of Peripheral Blood and Tissue Myeloid Cells. Phenotype for Precision Medicine in Patients With SARS-Cov-2 Infection
NCT05767853
Immune Cells Phenotypes During COVID-19
NCT04816760
Analysis of the Inflammatory Response and the Development of Humoral and Cellular Immunity in Patients With COVID-19
NCT04423640
Study of Kinetics and Efficacy of the Immune Response Against COVID-19 Among Hospital Staff
NCT04408001
Study of Virus-specific Lymphocytic Cell Populations in Non-invasive Nasal Mucosa Samples of MIS-C Patients
NCT05560906
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This infection drives a strong cytokine response. In patients developing SARS, a profound, paradoxical defect in IFN alpha and in the expression of genes responding to IFN alpha was discovered. IFNs are strong anti-viral proteins, used for the treatment of viral hepatitis. Type I IFNs, including IFN alpha, have ubiquitous receptors on almost every cell type. Type III IFNs, or IFN lambda, have a more restricted receptor expression, including on neutrophils. Their polymorphisms were already related to the prognosis of another ribonucleic acid (RNA) virus with mucosal entry, hepatitis C virus (HCV), especially in people with African origins.
Coronaviruses responsible for the previous SARS-Cov or Middle East respiratory syndrome coronavirus (MERS-Cov) epidemics induce a defective IFN signal transduction. Many other viral infection lead to desensitization. Moreover, IFN alpha by itself can lead to defective antiviral responses. At the immune cell level, lymphopenia with an increased neutrophil/lymphocyte ratio were noted in severe SARS-Cov2 case. New subpopulations of neutrophils have been characterized by phenotypic and proteomic studies, with inflammatory or suppressive functions.
It will be important to know if
* hyperactive or immunosuppressive myeloid cell differentiation is caused by SARS-Cov2 and can be inhibited specifically.
* some myeloid subpopulations
* correlate with the prognosis of the disease,
* myeloid cells have alternative receptors for SARS-Cov2,
* some IFN polymorphisms may correlate with prognosis and might be supplemented or inhibited for therapy.
The answers will be obtained through the primary and secondary outcome measures, as described below.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
SCREENING
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
group 1
Former mild SARS-Cov2 Pneumonia, 2 to 12 moths before, ≤ 5 L/mn Oxygen treatment
Blood sampling
Peripheral Blood sampling, 25 mL
Nasal Brushing
Nasal Brushing, facultative
Group 2
Former severe SARS-Cov2 Pneumonia, 2 to 12 moths before, \> 5 L/mn Oxygen treatment
Blood sampling
Peripheral Blood sampling, 25 mL
Nasal Brushing
Nasal Brushing, facultative
Group 3
Physician examination in the Pneumology ward, Cochin Hospital
Blood sampling
Peripheral Blood sampling, 25 mL
Nasal Brushing
Nasal Brushing, facultative
Group 4
Current hospitalization for Sars-Cov2 Pneumonia at Cochin Hospital
Blood sampling
Peripheral Blood sampling, 25 mL
Nasal Brushing
Nasal Brushing, facultative
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood sampling
Peripheral Blood sampling, 25 mL
Nasal Brushing
Nasal Brushing, facultative
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Sex : male or female
* French Social Security insurance
* Information and consent dated and signed \*
* Group 1 : inclusion 2 to 12 months after hospitalization for Covid-19 pneumonia with mild severity (oxygen treatment ≤5L/mn);
* Group 2 : 2 to 12 months after hospitalization for Covid-19 pneumonia with high severity (oxygen treatment \>5L/mn);
* Group 3 : external visit at Cochin Hospital, age- and sex -matched with Groups 1, 2, 4.
* Group 4 : inclusion during hospitalization for Covid-19, within the first month of symptoms.
Exclusion Criteria
* Chronic evolutive viral Infections (Hepatitis B or C, HIV)
* Ongoing chemotherapy or radiotherapy
* Participation in another research protocol with current exclusion period at the time of pre-inclusion (possible inclusion in an observational study
* Vulnerable person (pregnant, parturient woman, breastfeeding woman, person Under tutorship, person under arrest through judiciary or administrative decision )
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut National de la Santé Et de la Recherche Médicale, France
OTHER_GOV
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pierre-Régis Burgel, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Cochin Hospital
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Related Links
Access external resources that provide additional context or updates about the study.
Team Niedergang
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-A02700-39
Identifier Type: OTHER
Identifier Source: secondary_id
APHP201138
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.